Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Jun 22, 2022 1:56pm
186 Views
Post# 34774688

RE:RE:RE:RE:The 29 percent...

RE:RE:RE:RE:The 29 percent...He hasn't produced but nor has anyone else in management and the BOD.  To further explain that comment we've effectively issued 100 million shares without any of that value accruing in the share price.  I do agree with MM that lots has been achieved but not promoted.  But the most important phases are being continually fumbled.  So we've been seriously diluted with a languishing share price.  I do blame Seto but include management and the BOD to share the blame and shame.

So what do we do?  They could look to sell Dialco now if we can get decent value ($4 per share or above) for it.  We could cut a deal with Baxter to take over the EAA and PMX business with decent value now ($4 per share or above) or if that's not possible then a reasonable payment now ($3 per share) and a price adjustment on FDA approval of PMX.  That should take place if management and governance are not fit to take these great businesses to their conclusion efficiently.

If management and governance want credibility they must outline real plans and achieve success for these businesses.  The current exercise is focused on explaining why they haven't achieved any goals.  So  let's have action and no more excuses.

I'm pessimistic about management and governance, very optimistic for the two businesses and their value.  Let's sell to parties that are serious about the businesses and have the capability to take them to conclusion.  Unless management and those in governance can convince us they have a real plan and the personnel to execute that plan efficiently.

So my opinion is the entire management and BOD have failed so far and need to sell for proper value to capable hands or get going with making this successful.


<< Previous
Bullboard Posts
Next >>